Moderna Earnings Call Transcripts
Fiscal Year 2026
-
Revenue reached $1.9 billion in 2025, with cost reductions exceeding $2 billion and a strong cash position. Up to 10% revenue growth is guided for 2026, driven by international partnerships and new product launches. Key pipeline milestones include phase III oncology and norovirus data in 2026.
-
Revenue reached the high end of guidance in 2025, driven by strong COVID vaccine performance and international expansion. Growth is expected from a diversified vaccine and therapeutic pipeline, with major contributions from flu, norovirus, and oncology anticipated from 2027 onward. AI integration and disciplined capital allocation support cost control and future profitability.
-
The company is executing a strategic shift toward a diversified vaccine and oncology portfolio, with strong cost reductions, robust liquidity, and multiple late-stage pipeline catalysts expected through 2028. Key growth will come from new product launches, geographic expansion, and operational efficiencies.
Fiscal Year 2025
-
2025 saw $1.9B in revenue, a 30% drop in operating expenses, and a net loss of $2.8B, with strong cash reserves and pipeline progress. 2026 guidance projects up to 10% revenue growth, driven by international expansion and new product launches, despite regulatory setbacks for the flu vaccine.
-
Facing public scrutiny, the company projects COVID vaccine revenues of $1.6–$2 billion for 2025, with growth expected from new flu, norovirus, and combination vaccines. Oncology and rare disease programs advance, and a $1.5B credit facility supports flexibility.
-
A multi-year strategy aims to expand the vaccine franchise, invest in oncology and rare diseases, and boost efficiency via digital and AI transformation. Financial guidance targets cash break-even by 2028, with cost reductions and a strong cash position. Key pipeline products—mNEXSPIKE, flu, RSV, norovirus, and oncology—are expected to drive growth.
-
Shareholders approved a one-time stock option exchange for non-executive employees and a contingency to adjourn if needed, with both proposals passing by majority vote. No relevant shareholder questions were received, and final results will be filed with the SEC.
-
Q3 2025 revenue was $1 billion, with a net loss of $200 million and significant cost reductions. 2025 revenue guidance was narrowed, and cash cost projections improved by $900 million. Strategic partnerships and pipeline progress are expected to drive future growth.
-
mRNA-4359 demonstrated a 24% response rate in CPI-resistant melanoma with a favorable safety profile and strong immune activation, especially in PD-L1 positive patients. The oncology pipeline is expanding, with phase III INT data expected in 2026 and further translational research ongoing.
-
A diverse oncology portfolio is advancing with both individualized and off-the-shelf mRNA therapies, targeting multiple cancer types and stages. Key data readouts are expected in 2024 and 2026, with a focus on leveraging platform versatility, strategic partnerships, and translational insights to drive innovation and impact patient outcomes.
-
Recent regulatory wins and state-level policy changes are streamlining vaccine access and supporting strong retail demand. Strategic focus is on respiratory portfolio completion, cost control, and global expansion, with oncology and innovative vaccines driving future growth.
-
Q2 2025 saw revenue of $142M and a net loss of $825M, with cost reductions of 35–40% year-over-year. Three FDA approvals and strong flu vaccine data support future growth, while 2025 guidance was lowered due to shipment timing. AI adoption and a 10% workforce reduction drive further efficiency.
-
Oncology pipeline advances with pivotal INT phase III data expected in 2026 and expansion into multiple cancer types. Respiratory vaccine portfolio sees FDA approvals and strategic combo development. Cost controls and pipeline prioritization support a path to profitability by 2028.
-
Focused on respiratory vaccines and oncology, the business expects growth from new product launches and international expansion, with cost reductions supporting a return to profitability by 2028. Regulatory clarity and partnerships are key to advancing the pipeline.
-
Regulatory clarity has reduced uncertainty for 2025, with reaffirmed financial guidance and a focus on cost control. Multiple new vaccines and therapies are expected to drive revenue growth by 2027–2028, while the portfolio shifts toward oncology and away from new respiratory vaccines.
-
The company is focused on expanding its mRNA-based portfolio, stabilizing COVID and RSV sales, and launching new products while maintaining strict cost discipline. Regulatory clarity and AI-driven efficiencies support growth, with oncology as a major future driver.
-
Q1 2025 saw $108M in revenue and a $1B net loss, with cost reductions and stable U.S. COVID vaccine market share. Guidance for 2025 remains unchanged, with a focus on cost discipline, pipeline advancement, and break-even targeted by 2028.
-
Shareholders approved all management proposals, including director elections, executive compensation, and auditor ratification. Key priorities discussed were expanding the product pipeline, driving vaccine adoption, and maintaining regulatory engagement.
-
Leaders highlighted progress in oncology, rare disease, and vaccine programs, with key data readouts expected in 2025–2026. Financial guidance reflects market and regulatory uncertainties, while operational costs are being reduced. Early-stage oncology assets will advance internally, with openness to future partnerships.
-
Management reiterated 2025 vaccine sales guidance and outlined a path to cash breakeven by 2028, driven by product diversification and disciplined cost reductions. Key pipeline updates include RSV label expansion, a flu/COVID combo targeting 2026, and late-stage progress in norovirus, CMV, and oncology vaccines.
-
The company reported $3–$3.1 billion in 2024 sales, with $9.5 billion in cash and four positive phase III readouts. 2025 guidance is $1.5–$2.5 billion, reflecting market uncertainties and cost-saving measures. Key growth drivers include a robust late-stage pipeline, respiratory franchise, and oncology INT program.
Fiscal Year 2024
-
2024 saw $3.2B in revenue and a $3.6B net loss, with significant cost reductions and a strong cash position. Focus is on 10 high-value programs, with 2025 revenue guidance of $1.5–$2.5B and further cost cuts planned. Key pipeline and regulatory milestones are expected in 2025.
-
Late-stage mRNA vaccines for COVID, flu, and RSV are advancing, with a next-gen COVID/flu combo and a promising CMV vaccine nearing key data readouts. Retail and regulatory strategies aim to boost uptake, and the CMV vaccine could become a multi-billion dollar franchise.
-
The company is advancing a broad mRNA vaccine portfolio, with COVID and RSV vaccines on the market and several late-stage programs targeting regulatory filings and approvals by 2025. Key milestones for next year include pivotal data readouts and new product launches, supporting a strategy for significant revenue growth.
-
Execution remains steady amid political changes, with a stable COVID vaccine market and a robust pipeline including CMV, COVID-flu combo, and cancer vaccines. Ten product launches are planned in three years, aiming for profitability by 2028 and a self-funding model.
-
Political noise is not expected to impact vaccine markets, with strong Q3 results and stable COVID vaccination rates. The respiratory portfolio is expanding, with a focus on combination vaccines and new pipeline launches in CMV, norovirus, rare diseases, and oncology.
-
Leadership is expanding to cover the full product lifecycle as the company builds out commercial and marketing capabilities, targeting $3–$3.5 billion in revenue this year. Up to 10 product launches are planned over three years, with a strong pipeline in vaccines, oncology, and rare diseases.
-
Q3 revenue reached $1.9B with $13M net income, driven by early U.S. COVID vaccine launch and cost reductions. 2024 sales guidance is $3–$3.5B, with continued focus on cost efficiency, pipeline advancement, and international expansion.
-
Revised summary: Management is prioritizing 10 product launches in the next three years, focusing on respiratory, latent, oncology, and rare disease vaccines. Financial guidance now targets break-even in 2028 with reduced R&D investment. The pipeline shows strong progress, especially in next-gen vaccines and cancer therapy, with capital focused on high-impact launches.
-
Q2 2024 saw $241M in revenue and a $1.3B net loss, with strong cash reserves and significant cost reductions. Respiratory vaccine launches and pipeline progress continue amid competitive pressures and revised 2024 sales guidance of $3.0–$3.5B.
-
The discussion highlighted a robust pipeline across respiratory, oncology, and rare diseases, with strategic R&D prioritization and creative financing. Recent phase III data for the COVID-flu combo vaccine showed strong efficacy, while RSV and oncology programs demonstrated competitive profiles and durable results.
-
2024 guidance reflects conservative assumptions for APAs and flat U.S. COVID sales, with RSV and international COVID contributing $1 billion. RSV launch focuses on ease of use and competitive positioning, with long-term growth expected from expanded indications and international markets.
-
Three-year follow-up data show INT plus pembrolizumab delivers durable, significant improvements in recurrence-free and distant metastasis-free survival in high-risk melanoma, with a strong safety profile and consistent efficacy across biomarker subgroups. The pipeline is expanding into multiple tumor types, with manufacturing and regulatory strategies advancing to support broad adoption.